ERBB2 and ductal breast carcinoma in situ: Histological examination of surgical specimens revealed: 7 patients with high-risk DCIS, 78 patients with luminal A subtype, 39 patients with luminal B HER-, 24 patients with luminal B HER2+, 27 patients were identified as HER2−, while 17 patients were classified as triple-negative BC cases (Table 2).